Anti-IL-6 Antibody
Applied Molecular Evolution, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,065,488 | Anti-IL-6 Antibody In force · High confidence | Applied Molecular Evolution, Inc. | In force | High confidence | ||
| US 11,180,549 | Methods of Suppressing Rheumatoid Arthritis Using an Anti-IL-6 Antibody Term ended Term ended Apr 28, 2026 · High confidence | Applied Molecular Evolution, Inc. | Term ended | Term ended Apr 28, 2026 | Term ended Apr 28, 2026 | High confidence |
| US 9,340,613 | Anti-IL-6 Antibodies, Compositions, Methods and Uses Term ended Term ended Aug 16, 2026 · High confidence | Janssen Biotech, Inc. | Term ended | Term ended Aug 16, 2026 | Term ended Aug 16, 2026 | High confidence |
| Application 15/461,886 | Methods of Suppressing Rheumatoid Arthritis Using an ANTI-IL-6 Antibody Abandoned Abandoned Dec 30, 2019 | Janssen Biotech, Inc. | Abandoned | Abandoned Dec 30, 2019 | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Applied Molecular Evolution, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.